Antibody Systems

What Antibody Systems does

Antibody Systems, Inc. (ASI) is a privately held Texas corporation founded in 1984 and headquartered in Hurst, TX, specializing in the procurement, processing, and sale of diagnostic and therapeutic biological materials for research and manufacturing applications. The company's core catalog comprises human serum, plasma, peripheral blood mononuclear cells (PBMCs) isolated via Ficoll centrifugation, and human tissue samples spanning infectious diseases including Chagas, Chikungunya, COVID-19/SARS-CoV-2, Dengue, Hepatitis B, HTLV, Marburg, Oropouche, Rubella, Toxo, Yellow Fever, and Zika. It also supplies FDA Zika EUA-compliant cross-reactivity testing samples for diagnostic kit manufacturers. ASI's differentiated offering is the Expeditionary Biology Division, which sources rare antibodies and proteins from wild-caught exotic and endangered species worldwide, drawing on 25+ years of field experience navigating foreign regulations and geographic health conditions.

The company's business model is built on one-time sales of biological materials, custom procurement of rare samples, and contract research collaborations under Cooperative Research and Development Agreements (CRADAs) with the CDC, Vector (Russian BL4 Viral Research Center), USAMRIID, and the University of Mexico Medical School. Revenue mechanics rely entirely on direct, contact-based sales (phone, fax, email) and a downloadable PDF product catalog — no e-commerce, no public pricing, and no intermediary distribution. Customers are primarily pharmaceutical companies (drug development and diagnostic kit manufacturing), university research institutions, and government health/research agencies. The company is led by President Terry Fredeking, who also heads the Expeditionary Biology Division, and operates with 11-50 employees, consistent with a niche specialty supplier rather than a scaled reagent manufacturer. Strategic research assets include a CDC co-discovered viral vector for gene therapy and proprietary work on Komodo dragon-derived antibiotics, both of which represent potential upside optionality.

Name

Antibody Systems

Legal name

Antibody Systems, Inc.

Website

https://antibodysystems.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

11–50 employees

Short description

Antibody Systems is a Texas-based specialty supplier of human serum, plasma, PBMC, and tissue samples for infectious disease research, with an Expeditionary Biology Division that sources rare antibodies from exotic species for pharmaceutical, academic, and government customers worldwide.

Ownership category

akta.pro rank

Product category

Biological Research Materials

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Biological research materials
• Human serum samples
• Diagnostic plasma samples
• Peripheral blood mononuclear cells
• Rare animal antibodies

Headquarters

HQ city

Hurst

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Biological Materials Sales: One-time sales of diagnostic and therapeutic biological materials including human serum, plasma, PBMCs, and tissue samples. Products sold to pharmaceutical companies for drug development and diagnostic test kit manufacturing. Available for national and international corporations.
2. Custom Research Sample Procurement: Custom procurement of rare and exotic biological products for specific research needs. Expeditionary Biology Division specializes in collecting plasma and serum containing rare antibodies and proteins from unusual species for pharmaceutical and university research.
3. Contract Research Services: Research and development collaboration through CRADA agreements with CDC, Vector, and university partners. Includes vaccine development, hyperimmune plasma production, and infectious disease diagnostic control development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Antibody Systems, Inc. (ASI) procures, processes, and sells diagnostic and therapeutic biological materials for research and manufacturing applications. Core products include human serum, plasma, peripheral blood mononuclear cells (PBMCs), and tissue samples covering infectious diseases such as Chagas, Chikungunya, COVID-19, Dengue, Hepatitis B, Zika, and others, supplied primarily to pharmaceutical companies, diagnostic test kit manufacturers, university researchers, and government agencies. An Expeditionary Biology Division additionally sources rare animal antibodies and exotic biological products from wild living animals worldwide.

Product overview

Antibody Systems (ASI) operates as a major producer of diagnostic and therapeutic biological materials for research and manufacturing applications. The company offers a unified portfolio centered on human biological samples including serum, plasma, and peripheral blood mononuclear cells (PBMCs) for infectious disease research, complemented by human tissue samples and a specialized Expeditionary Biology Division for sourcing rare animal antibodies. The company also maintains an active R&D program focused on immunological modulators, vaccine development, and novel antibiotic discovery.

Differentiator

Problem solved

Functional benefit

Brands

• ASI Products Division: Products division of Antibody Systems, Inc. supplying biological research samples including serum, plasma, and tissue samples.
• Expeditionary Biology Division

Products and services

• Human Serum and Plasma Samples
• Peripheral Blood Mononuclear Cell (PBMC) Samples
• Human Tissue Research Samples
• Zika Research Sample Portfolio
• Expeditionary Biology Field Collection Services
• Immune Research and Development Program

Quantifiable outcome

• 50-100 million dengue infections occur worldwide annually per WHO estimates, representing significant market need for treatments and diagnostics
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Centers for Disease Control and Prevention (CDC)coreStrategic or Co-development PartnerCRADA (Cooperative Research and Development Agreement) partnership with CDC. Co-discovered a viral vector that could be used for gene delivery or vaccine development. The virus meets critical criteria for safe gene therapy applications: cannot cause human illness, is not in the general population, remains in host for lifetime, and cannot transmit human-to-human.
• Vector (Russian BL4 Viral Research Center)coreStrategic or Co-development PartnerCRADA partnership with Vector, a Russian biotech institute and BL4 viral research center. ASI employed Russian scientists, equipped laboratories, and funded testing focused on pharmaceutical drug applications for treatment of bioweapons and dangerous pathogens. Research aimed at finding new prophylaxis to counter biological weapons of mass destruction.
• University of Mexico Medical School in MeridacoreStrategic or Co-development PartnerResearch collaboration with University of Mexico Medical School in Merida, Yucatan focused on finding an inexpensive but effective treatment for dengue fever. Research is expanding into Colombia and Venezuela. WHO has labeled dengue a pandemic threat with 50-100 million annual infections worldwide.
• USAMRIID (United States Army Medical Institute of Infectious Disease)coreStrategic or Co-development PartnerJoint projects with USAMRIID biological level 4 (BL4) laboratory to produce effective results against Ebola and other dangerous hemorrhagic pathogens. Collaborative research focused on treatments for hemorrhagic diseases.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Bio-Techne: Bio-Techne is a major life sciences tools company offering reagents, proteins, antibodies, and diagnostic assay components. It overlaps with ASI in supplying antibodies, assay reagents, and biological materials to research and clinical diagnostics customers.
• ATCC: ATCC is a global biological resource center providing authenticated cell lines, microbial strains, and biological materials for research. As a broad incumbent, it overlaps with ASI in supplying standardized biological materials to research institutions and pharma.

Direct peers

• Discovery Life Sciences: Discovery Life Sciences provides biospecimens, including human tissue, plasma, serum, and cell products for research, diagnostic, and therapeutic development. It overlaps with ASI in serving pharma and diagnostic test kit manufacturers with disease-state samples and rare antibody reagents.
• HemaCare (Charles River Laboratories): HemaCare, now part of Charles River, specializes in human-derived biological products including fresh and frozen PBMCs, plasma, and apheresis collections for cell therapy and research. It competes with ASI's PBMC and plasma offerings to pharma and academic customers.
• ProteoGenex: ProteoGenex provides human tissue specimens and biofluids for research, with a focus on disease-state samples for pharma and diagnostic development. It directly competes with ASI's tissue and biofluid offerings to research and diagnostic manufacturers.
• BioIVT: BioIVT is a leading global provider of biological specimens, including human and animal tissues, serum, plasma, and PBMCs for research and diagnostic development. It directly competes with ASI in supplying pharma, biotech, and diagnostic manufacturers with biospecimens and rare-disease samples.
• iSpecimen: iSpecimen operates a marketplace connecting researchers with human biospecimens, including serum, plasma, and tissue samples from patients with specific disease conditions. It competes with ASI by offering a more digital, scalable procurement model for rare-disease samples.
• Sanguine Biosciences: Sanguine Biosciences provides biospecimen collection and management services for biomedical research, including patient-derived samples and custom cohort recruitment. It overlaps with ASI in serving pharma/biotech with disease-specific human samples for research.

Emerging players

• StemCell Technologies: StemCell Technologies is a specialty provider of cell isolation products, including PBMCs, primary cells, and cell culture media. It partially overlaps with ASI's PBMC product line, primarily serving academic and translational research customers.
• Genezen: Genezen is a viral vector CDMO focused on lentiviral and adeno-associated viral (AAV) production for gene therapy. It is comparable to ASI's proprietary viral vector work, representing potential partnership, licensing, or competitive overlap in gene delivery technologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antibody Systems